Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma
Authors
Keywords
-
Journal
NATURE MEDICINE
Volume 26, Issue 2, Pages 270-280
Publisher
Springer Science and Business Media LLC
Online
2020-01-21
DOI
10.1038/s41591-019-0737-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Computational Modeling of Realistic Cell Membranes
- (2019) Siewert J. Marrink et al. CHEMICAL REVIEWS
- Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T-cells
- (2019) Philipp Karschnia et al. BLOOD
- Toxicities of CD19 CAR-T cell immunotherapy
- (2019) Alexandre V. Hirayama et al. AMERICAN JOURNAL OF HEMATOLOGY
- A safe and potent anti-CD19 CAR T cell therapy
- (2019) Zhitao Ying et al. NATURE MEDICINE
- Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR
- (2019) Sara Ghorashian et al. NATURE MEDICINE
- T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
- (2018) Jennifer N. Brudno et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical and Biologic Correlates of Neurotoxicity Associated with CAR T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL)
- (2018) Bianca D. Santomasso et al. Cancer Discovery
- Chimeric Antigen Receptor T Cell–Mediated Neurotoxicity in Nonhuman Primates
- (2018) Agne Taraseviciute et al. Cancer Discovery
- In vivo fate and activity of second versus third-generation D19-specific CAR-T cells in B-cell non-Hodgkin lymphomas
- (2018) Carlos A. Ramos et al. MOLECULAR THERAPY
- ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells
- (2018) Daniel W Lee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
- (2018) Jennifer N. Brudno et al. BLOOD REVIEWS
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency
- (2018) Judith Feucht et al. NATURE MEDICINE
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- A novel pathway of LPS uptake through syndecan-1 leading to pyroptotic cell death
- (2018) Shigetoshi Yokoyama et al. eLife
- Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels
- (2017) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains
- (2017) Leah Alabanza et al. MOLECULAR THERAPY
- Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy
- (2017) James N. Kochenderfer et al. MOLECULAR THERAPY
- Chimeric antigen receptor T-cell therapies for lymphoma
- (2017) Jennifer N. Brudno et al. Nature Reviews Clinical Oncology
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
- (2017) Sattva S. Neelapu et al. Nature Reviews Clinical Oncology
- Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
- (2017) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
- (2017) Juliane Gust et al. Cancer Discovery
- CAR-T Cell Therapy for Lymphoma
- (2016) Carlos A. Ramos et al. Annual Review of Medicine
- Toxicities of chimeric antigen receptor T cells: recognition and management
- (2016) Jennifer N. Brudno et al. BLOOD
- Driving gene-engineered T cell immunotherapy of cancer
- (2016) Laura A Johnson et al. CELL RESEARCH
- Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma
- (2016) Stephanie L. Goff et al. JOURNAL OF CLINICAL ONCOLOGY
- Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease
- (2016) Jennifer N. Brudno et al. JOURNAL OF CLINICAL ONCOLOGY
- Energetic and flexibility properties captured by long molecular dynamics simulations of a membrane-embedded pMHCII–TCR complex
- (2016) Martiniano Bello et al. Molecular BioSystems
- Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells
- (2016) Cameron J. Turtle et al. Science Translational Medicine
- Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
- (2016) D. T. Teachey et al. Cancer Discovery
- CAR therapy: the CD19 paradigm
- (2015) Michel Sadelain JOURNAL OF CLINICAL INVESTIGATION
- Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
- (2015) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
- (2011) J. N. Kochenderfer et al. BLOOD
- CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients
- (2011) Barbara Savoldo et al. JOURNAL OF CLINICAL INVESTIGATION
- Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens
- (2010) E. H. Warren et al. BLOOD
- Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
- (2010) J. N. Kochenderfer et al. BLOOD
- Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells
- (2010) J. N. Kochenderfer et al. BLOOD
- Rapid Production of Clinical-Grade Gammaretroviral Vectors in Expanded Surface Roller Bottles Using a “Modified” Step-Filtration Process for Clearance of Packaging Cells
- (2010) Steven A. Feldman et al. HUMAN GENE THERAPY
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
- (2010) Richard A Morgan et al. MOLECULAR THERAPY
- Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor
- (2009) James N. Kochenderfer et al. JOURNAL OF IMMUNOTHERAPY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now